Cargando…

Selective stimulation of colonic L cells improves metabolic outcomes in mice

AIMS/HYPOTHESIS: Insulin-like peptide-5 (INSL5) is found only in distal colonic L cells, which co-express glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). GLP-1 is a well-known insulin secretagogue, and GLP-1 and PYY are anorexigenic, whereas INSL5 is considered orexigenic. We aimed to clarify...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Jo E., Miedzybrodzka, Emily L., Foreman, Rachel E., Woodward, Orla R. M., Kay, Richard G., Goldspink, Deborah A., Gribble, Fiona M., Reimann, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286941/
https://www.ncbi.nlm.nih.gov/pubmed/32342115
http://dx.doi.org/10.1007/s00125-020-05149-w
_version_ 1783544963197304832
author Lewis, Jo E.
Miedzybrodzka, Emily L.
Foreman, Rachel E.
Woodward, Orla R. M.
Kay, Richard G.
Goldspink, Deborah A.
Gribble, Fiona M.
Reimann, Frank
author_facet Lewis, Jo E.
Miedzybrodzka, Emily L.
Foreman, Rachel E.
Woodward, Orla R. M.
Kay, Richard G.
Goldspink, Deborah A.
Gribble, Fiona M.
Reimann, Frank
author_sort Lewis, Jo E.
collection PubMed
description AIMS/HYPOTHESIS: Insulin-like peptide-5 (INSL5) is found only in distal colonic L cells, which co-express glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). GLP-1 is a well-known insulin secretagogue, and GLP-1 and PYY are anorexigenic, whereas INSL5 is considered orexigenic. We aimed to clarify the metabolic impact of selective stimulation of distal colonic L cells in mice. METHODS: Insl5 promoter-driven expression of Gq-coupled Designer Receptor Exclusively Activated by Designer Drugs (DREADD) was employed to activate distal colonic L cells (L(distalDq)). IPGTT and food intake were assessed with and without DREADD activation. RESULTS: L(distalDq) cell stimulation with clozapine N-oxide (CNO; 0.3 mg/kg i.p.) increased plasma GLP-1 and PYY (2.67- and 3.31-fold, respectively); INSL5 was not measurable in plasma but was co-secreted with GLP-1 and PYY in vitro. IPGTT (2 g/kg body weight) revealed significantly improved glucose tolerance following CNO injection. CNO-treated mice also exhibited reduced food intake and body weight after 24 h, and increased defecation, the latter being sensitive to 5-hydroxytryptamine (5-HT) receptor 3 inhibition. Pre-treatment with a GLP1 receptor-blocking antibody neutralised the CNO-dependent improvement in glucose tolerance but did not affect the reduction in food intake, and an independent group of animals pair-fed to the CNO-treatment group demonstrated attenuated weight loss. Pre-treatment with JNJ-31020028, a neuropeptide Y receptor type 2 antagonist, abolished the CNO-dependent effect on food intake. Assessment of whole body physiology in metabolic cages revealed L(distalDq) cell stimulation increased energy expenditure and increased activity. Acute CNO-induced food intake and glucose homeostasis outcomes were maintained after 2 weeks on a high-fat diet. CONCLUSIONS/INTERPRETATION: This proof-of-concept study demonstrates that selective distal colonic L cell stimulation has beneficial metabolic outcomes. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-020-05149-w) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-7286941
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72869412020-06-16 Selective stimulation of colonic L cells improves metabolic outcomes in mice Lewis, Jo E. Miedzybrodzka, Emily L. Foreman, Rachel E. Woodward, Orla R. M. Kay, Richard G. Goldspink, Deborah A. Gribble, Fiona M. Reimann, Frank Diabetologia Article AIMS/HYPOTHESIS: Insulin-like peptide-5 (INSL5) is found only in distal colonic L cells, which co-express glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). GLP-1 is a well-known insulin secretagogue, and GLP-1 and PYY are anorexigenic, whereas INSL5 is considered orexigenic. We aimed to clarify the metabolic impact of selective stimulation of distal colonic L cells in mice. METHODS: Insl5 promoter-driven expression of Gq-coupled Designer Receptor Exclusively Activated by Designer Drugs (DREADD) was employed to activate distal colonic L cells (L(distalDq)). IPGTT and food intake were assessed with and without DREADD activation. RESULTS: L(distalDq) cell stimulation with clozapine N-oxide (CNO; 0.3 mg/kg i.p.) increased plasma GLP-1 and PYY (2.67- and 3.31-fold, respectively); INSL5 was not measurable in plasma but was co-secreted with GLP-1 and PYY in vitro. IPGTT (2 g/kg body weight) revealed significantly improved glucose tolerance following CNO injection. CNO-treated mice also exhibited reduced food intake and body weight after 24 h, and increased defecation, the latter being sensitive to 5-hydroxytryptamine (5-HT) receptor 3 inhibition. Pre-treatment with a GLP1 receptor-blocking antibody neutralised the CNO-dependent improvement in glucose tolerance but did not affect the reduction in food intake, and an independent group of animals pair-fed to the CNO-treatment group demonstrated attenuated weight loss. Pre-treatment with JNJ-31020028, a neuropeptide Y receptor type 2 antagonist, abolished the CNO-dependent effect on food intake. Assessment of whole body physiology in metabolic cages revealed L(distalDq) cell stimulation increased energy expenditure and increased activity. Acute CNO-induced food intake and glucose homeostasis outcomes were maintained after 2 weeks on a high-fat diet. CONCLUSIONS/INTERPRETATION: This proof-of-concept study demonstrates that selective distal colonic L cell stimulation has beneficial metabolic outcomes. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-020-05149-w) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2020-04-27 2020 /pmc/articles/PMC7286941/ /pubmed/32342115 http://dx.doi.org/10.1007/s00125-020-05149-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lewis, Jo E.
Miedzybrodzka, Emily L.
Foreman, Rachel E.
Woodward, Orla R. M.
Kay, Richard G.
Goldspink, Deborah A.
Gribble, Fiona M.
Reimann, Frank
Selective stimulation of colonic L cells improves metabolic outcomes in mice
title Selective stimulation of colonic L cells improves metabolic outcomes in mice
title_full Selective stimulation of colonic L cells improves metabolic outcomes in mice
title_fullStr Selective stimulation of colonic L cells improves metabolic outcomes in mice
title_full_unstemmed Selective stimulation of colonic L cells improves metabolic outcomes in mice
title_short Selective stimulation of colonic L cells improves metabolic outcomes in mice
title_sort selective stimulation of colonic l cells improves metabolic outcomes in mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286941/
https://www.ncbi.nlm.nih.gov/pubmed/32342115
http://dx.doi.org/10.1007/s00125-020-05149-w
work_keys_str_mv AT lewisjoe selectivestimulationofcoloniclcellsimprovesmetabolicoutcomesinmice
AT miedzybrodzkaemilyl selectivestimulationofcoloniclcellsimprovesmetabolicoutcomesinmice
AT foremanrachele selectivestimulationofcoloniclcellsimprovesmetabolicoutcomesinmice
AT woodwardorlarm selectivestimulationofcoloniclcellsimprovesmetabolicoutcomesinmice
AT kayrichardg selectivestimulationofcoloniclcellsimprovesmetabolicoutcomesinmice
AT goldspinkdeboraha selectivestimulationofcoloniclcellsimprovesmetabolicoutcomesinmice
AT gribblefionam selectivestimulationofcoloniclcellsimprovesmetabolicoutcomesinmice
AT reimannfrank selectivestimulationofcoloniclcellsimprovesmetabolicoutcomesinmice